Trial Profile
A PHASE 2, 12 WEEK, ADAPTIVE, OPEN LABEL, SEQUENTIAL COHORT TRIAL TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF 06730512 FOLLOWING MULTIPLE DOSES IN ADULT SUBJECTS WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Feb 2024
Price :
$35
*
At a glance
- Drugs PF-06730512 (Primary)
- Indications Focal segmental glomerulosclerosis
- Focus Therapeutic Use
- Acronyms PODO
- Sponsors Pfizer
- 07 Apr 2023 Status changed from active, no longer recruiting to discontinued.
- 17 Mar 2023 This trial has been completed in Poland, according to European Clinical Trials Database record.
- 11 Mar 2023 This trial has been completed in Germany, according to European Clinical Trials Database record.